A retrospective, non-interventional study of breast cancer patients diagnosed with ER+/HER2 negative, locally advanced or metastatic breast cancer treated with palbociclib in Denmark.
Rasmus GarlyTobias BergMaj-Britt JensenAnn KnoopLone VolmerVesna GlavicicHumma KhanPeter Bo PoulsenJens OlsenIben KümlerPublished in: Acta oncologica (Stockholm, Sweden) (2023)
In this real-world study, treatment with palbociclib combination therapy met the standards of efficacy set by the phase III trials, PALOMA-2 and PALOMA-3, and the standards set by real-world studies in other countries. The study showed significantly different outcomes in terms of PFS and OS in endocrine sensitive patients comparing AI vs. fulvestrant as endocrine backbone to palbociclib as first-line therapy.
Keyphrases
- metastatic breast cancer
- combination therapy
- clinical trial
- locally advanced
- newly diagnosed
- phase iii
- squamous cell carcinoma
- adipose tissue
- radiation therapy
- type diabetes
- prognostic factors
- metabolic syndrome
- machine learning
- neoadjuvant chemotherapy
- lymph node
- replacement therapy
- bone marrow
- smoking cessation
- study protocol
- phase ii study
- peritoneal dialysis